Cutia Therapeutics (2487) Stock Statistics & Valuation Metrics

Cutia Therapeutics has a market cap or net worth of HK$1.31B. The enterprise value is HK$1.18B.

Cutia Therapeutics has 364,730,870 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cutia Therapeutics’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -25.31%.

The current PE Ratio of Cutia Therapeutics is ―. Cutia Therapeutics’s PEG ratio is 0.15.

In the last 12 months, Cutia Therapeutics had revenue of 336.15M and earned -340.19M in profits. Earnings per share was -1.03.

In the last 12 months, operating cash flow was -119.63M and capital expenditures -3.26M, giving a free cash flow of -122.89M billion.

Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Cutia Therapeutics upcoming earnings date is Aug 27, 2026, Before Open (Confirmed).

Cutia Therapeutics as a current ratio of 3.87, with Debt / Equity ratio of 35.85%

In the past 12 months, Cutia Therapeutics has paid 0.00 in taxes.

Cutia Therapeutics EV to EBITDA ratio is -5.04, with an EV/FCF ratio of -4.62.

Cutia Therapeutics has HK$789.16M in cash and marketable securities with HK$317.53M in debt, giving a net cash position of HK$471.64M billion.

Gross margin is 58.25%, with operating margin of -91.81%, and net profit margin of -101.20%.

The average price target for Cutia Therapeutics is HK$7.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy